{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:59:53Z","timestamp":1791489593657,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.intimp.2019.105868","type":"journal-article","created":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T17:22:04Z","timestamp":1567444924000},"page":"105868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Changing trends in IVIG use in pediatric patients: A retrospective review of practices in a network of major USA pediatric hospitals"],"prefix":"10.1016","volume":"76","author":[{"given":"Alfred","family":"Balch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Wilkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Thorell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Pavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.T.","family":"Sherwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Y.","family":"Enioutina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2019.105868_bb0005","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","article-title":"Agammaglobulinemia","volume":"9","author":"Bruton","year":"1952","journal-title":"Pediatrics"},{"key":"10.1016\/j.intimp.2019.105868_bb0010","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.iac.2008.07.001","article-title":"Immunoglobulin replacement therapy in children","volume":"28","author":"Garcia-Lloret","year":"2008","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"10.1016\/j.intimp.2019.105868_bb0015","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency Committee of the American Academy of allergy, asthma and immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2019.105868_bb0020","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2019.105868_bb0025","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2019.105868_bb0030","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s10875-013-9912-3","article-title":"Prioritization of evidence-based indications for intravenous immunoglobulin","volume":"33","author":"Orange","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.intimp.2019.105868_bb0035","doi-asserted-by":"crossref","unstructured":". Goddard, E. A. (2008) Goddard EA. Curr. Allergy Clin. Immunol. 21, 26\u201331.","DOI":"10.1007\/978-1-60327-400-5_3"},{"key":"10.1016\/j.intimp.2019.105868_bb0040","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0887-7963(03)00038-5","article-title":"Risks associated with the use of intravenous immunoglobulin","volume":"17","author":"Pierce","year":"2003","journal-title":"Transfus. Med. Rev."},{"key":"10.1016\/j.intimp.2019.105868_bb0045","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.mjafi.2013.05.011","article-title":"Intravenous immunoglobulin in pediatrics: a review","volume":"70","author":"Prasad","year":"2014","journal-title":"Med. J. Armed Forces India"},{"key":"10.1016\/j.intimp.2019.105868_bb0050","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1080\/21645515.2015.1061161","article-title":"The usefulness of immunotherapy in pediatric neurodegenerative disorders: a systematic review of literature data","volume":"11","author":"Vitaliti","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.intimp.2019.105868_bb0055","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00246-014-1016-1","article-title":"Epidemiology of immunoglobulin resistant Kawasaki disease: results from a large, national database","volume":"36","author":"Moffett","year":"2015","journal-title":"Pediatr. Cardiol."},{"key":"10.1016\/j.intimp.2019.105868_bb0060","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0000000000002422","article-title":"Diagnostic and treatment trends in children with Kawasaki disease in the United States, 2006-2015","author":"Dominguez","year":"2019","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.intimp.2019.105868_bb0065","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41598-019-46888-0","article-title":"Role of intravenous immunoglobulin therapy in the survival rate of pediatric patients with acute myocarditis: a systematic review and meta-analysis","volume":"9","author":"Yen","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2019.105868_bb0070","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1536\/ihj.18-299","article-title":"Intravenous immunoglobulin therapy for acute myocarditis in children and adults","volume":"60","author":"Huang","year":"2019","journal-title":"Int. Heart J."},{"issue":"Suppl. 3","key":"10.1016\/j.intimp.2019.105868_bb0075","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1542\/peds.2012-0055I","article-title":"Standard 6: age groups for pediatric trials","volume":"129","author":"Williams","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.intimp.2019.105868_bb0080","unstructured":"Mortality Risk Adjustment Methodology for University Health System's Clinical Data Base (2008) Available at: https:\/\/archive.ahrq.gov\/professionals\/quality-patient-safety\/quality-resources\/tools\/mortality\/Meurer.pdf; University HealthSystem Consortium. Last accesed April 30, 2019."},{"key":"10.1016\/j.intimp.2019.105868_bb0090","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1385\/CRIAI:29:3:307","article-title":"Uncovering the hidden potential of intravenous immunoglobulin as an anticancer therapy","volume":"29","author":"Sapir","year":"2005","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.intimp.2019.105868_bb0095","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1586\/1744666X.2015.1044980","article-title":"The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease","volume":"11","author":"Burns","year":"2015","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.intimp.2019.105868_bb0100","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1385\/CRIAI:29:3:185","article-title":"Facing the enigma of immunomodulatory effects of intravenous immunoglobulin","volume":"29","author":"Sapir","year":"2005","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.intimp.2019.105868_bb0105","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/intimm\/dxx039","article-title":"IVIG-mediated effector functions in autoimmune and inflammatory diseases","volume":"29","author":"Galeotti","year":"2017","journal-title":"Int. Immunol."},{"key":"10.1016\/j.intimp.2019.105868_bb0110","first-page":"365","article-title":"Diagnosis and management of Kawasaki disease","volume":"91","author":"Saguil","year":"2015","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.intimp.2019.105868_bb0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1546-0096-12-37","article-title":"Kawasaki disease in children and adolescents: clinical data of Kawasaki patients in a western region (Tyrol) of Austria from 2003-2012","volume":"12","author":"Binder","year":"2014","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"10.1016\/j.intimp.2019.105868_bb0120","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1537-2995.2006.00792.x","article-title":"Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature","volume":"46","author":"Darabi","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.intimp.2019.105868_bb0125","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(01)07219-1","article-title":"Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study","volume":"358","author":"Kuhne","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2019.105868_bb0130","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood-2012-12-466375","article-title":"Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS)","volume":"121","author":"Neunert","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2019.105868_bb0135","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/00043426-200308000-00017","article-title":"Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis","volume":"25","author":"Butros","year":"2003","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2019.105868_bb0140","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/10245332.2016.1219497","article-title":"Advances in the pathophysiology of primary immune thrombocytopenia","volume":"22","author":"Perera","year":"2017","journal-title":"Hematology"},{"key":"10.1016\/j.intimp.2019.105868_bb0145","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0140-6736(94)92205-5","article-title":"Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura","volume":"344","author":"Blanchette","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2019.105868_bb0150","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1056\/NEJM198810063191403","article-title":"Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial","volume":"319","author":"Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic, L","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2019.105868_bb0155","unstructured":". Howlader, N., Noone, A. M., Krapcho, M., Miller, D. J., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D. R., Chen, H. S., Feuer, E. J., and Cronin, K. A. (April 15, 2019) SEER Cancer Statistics Review, 1975-2016, Section 28 Childhood Cancer by Site Incidence, Survival and Mortalitybased on November 2018 SEER Data Submission, Posted to the SEER Web Site. Available at: https:\/\/seer.cancer.gov\/csr\/1975_2016\/results_merged\/sect_28_childhood_cancer.pdf Last Accessed April 30 2019. (Institute, N. C., ed), Bethesda, MD."},{"key":"10.1016\/j.intimp.2019.105868_bb0160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7812\/TPP\/17-141","article-title":"Prevalence and safety of intravenous immunoglobulin administration during maintenance chemotherapy in children with acute lymphoblastic leukemia in first complete remission: a health maintenance organization perspective","volume":"22","author":"Van Winkle","year":"2018","journal-title":"Perm. J."},{"key":"10.1016\/j.intimp.2019.105868_bb0165","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","article-title":"Guillain-Barre syndrome","volume":"366","author":"Hughes","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2019.105868_bb0170","first-page":"230","article-title":"Guillain-Barre syndrome and its association with infectious factors","volume":"39","author":"Grygorczuk","year":"2005","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.intimp.2019.105868_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CND.0b013e3181aaa968","article-title":"Guillain-Barre syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention\/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005)","volume":"11","author":"Souayah","year":"2009","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"10.1016\/j.intimp.2019.105868_bb0180","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1345\/aph.1P078","article-title":"Guillain-Barre syndrome following H1N1 immunization in a pediatric patient","volume":"44","author":"Tremblay","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.intimp.2019.105868_bb0185","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(96)07408-9","article-title":"Measles vaccination and Guillain-Barre syndrome","volume":"349","author":"da Silveira","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2019.105868_bb0190","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jama.2009.1201","article-title":"Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine","volume":"302","author":"Slade","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2019.105868_bb0195","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1007\/s10875-010-9407-4","article-title":"IVIG treatment and prognosis in Guillain-Barre syndrome","volume":"30","author":"van Doorn","year":"2010","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.intimp.2019.105868_bb0200","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000184748","article-title":"The epidemiology of Guillain-Barre syndrome worldwide. A systematic literature review","volume":"32","author":"McGrogan","year":"2009","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.intimp.2019.105868_bb0205","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1212\/WNL.0b013e31820e7b62","article-title":"Recognizing Guillain-Barre syndrome in preschool children","volume":"76","author":"Roodbol","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2019.105868_bb0210","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain-Barre syndrome","author":"Hughes","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.intimp.2019.105868_bb0215","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.61.6.736","article-title":"Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"61","author":"Hughes","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2019.105868_bb0220","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/s-2007-981686","article-title":"Clinical presentation and course of childhood Guillain-Barre syndrome: a prospective multicentre study","volume":"38","author":"Korinthenberg","year":"2007","journal-title":"Neuropediatrics"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919313803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919313803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:46:17Z","timestamp":1786376777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576919313803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":43,"alternative-id":["S1567576919313803"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2019.105868","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changing trends in IVIG use in pediatric patients: A retrospective review of practices in a network of major USA pediatric hospitals","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2019.105868","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105868"}}